1. Discovery of small-molecule positive allosteric modulators of Parkin E3 ligase.
- Author
-
Shlevkov E, Murugan P, Montagna D, Stefan E, Hadzipasic A, Harvey JS, Kumar PR, Entova S, Bansal N, Bickford S, Wong LY, Hirst WD, Weihofen A, and Silvian LF
- Abstract
Pharmacological activation of the E3 ligase Parkin represents a rational therapeutic intervention for the treatment of Parkinson's disease. Here we identify several compounds that enhance the activity of wildtype Parkin in the presence of phospho-ubiquitin and act as positive allosteric modulators (PAMs). While these compounds activate Parkin in a series of biochemical assays, they do not act by thermally destabilizing Parkin and fail to enhance the Parkin translocation rate to mitochondria or to enact mitophagy in cell-based assays. We conclude that in the context of the cellular milieu the therapeutic window to pharmacologically activate Parkin is very narrow., Competing Interests: All authors are employees and shareholders at Biogen., (© 2021 The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF